

The Biopharmaceuticals sector in Japan: Government regulations, the competitive situation and how to find an entry point - A primer for European SMEs.

July 2019

Professor Rolf Schmid



Contents

1	Executive summary	4
2	Scope of the report	6
3	Introduction	7
4	Japan’s healthcare system	8
4.1	Introduction	8
4.2	Healthcare expenditure	8
4.3	Japan’s Pharmaceutical and Biopharmaceutical Industry	10
4.4	Public R&D in biomedicine	11
4.5	Japan Agency for Medical Research and Development (AMED)	11
4.6	Japan’s market for pharmaceuticals and biopharmaceuticals	12
4.7	Japan’s biopharmaceutical market: the competitive situation	12
4.8	Biopharmaceuticals	13
4.9	Biosimilars	15
4.10	Cell products	17
4.11	Genomic medicine and gene therapy	19
5	Market access	19
5.1	Categories of pharmaceutical and biopharmaceutical products	19
5.2	The Pharmaceutical Affairs Law and the Pharmaceutical and Medical Devices Agency (PMDA)	20
5.3	Authorisation requirements for marketing	21
5.4	Authorisation requirements for manufacturing	22
5.5	Regulatory review and clinical trials	22
5.6	Approval criteria for generics	24
5.7	Orphan drugs	24
5.8	Innovative products and bio-products: the forerunner (“Sakigake”) procedure	24
5.9	Pricing	25
5.10	Marketing and sales	26
5.11	Postmarketing and Good Vigilance Practice (GVP)	27
6	Cultural business practice	28
7	Opportunities and access points	29
7.1	General remarks	29
7.2	Access points	29
7.3	PMDA’ consulting services are indispensable	30
7.4	Further recommendations to SMEs	30
8	Actors, clusters, fairs	32
8.1	in Japan	32
8.2	in Europe	33
8.3	Pharmaceuticals-related Trade Fairs in Japan	34
9	Literature	34